Clinical & Real-World Data | Tardive Dyskinesia (TD) | AUSTEDO ...
See the tardive dyskinesia (TD) clinical trial results for AUSTEDO. See Prescribing Information, including Boxed Warning.
Clinical Studies Results | AUSTEDO (deutetrabenazine)
View the clinical study details for AUSTEDO (deutetrabenazine) tablets and treatment of Tardive Dyskinesia. See safety info and boxed warning.
New 48-Week Remission Data on Ingrezza for the Treatment of Tardive …
Mar 20, 2025 · Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.
Study Explores Tardive Dyskinesia Outcomes With …
Nov 12, 2024 · Teva also announced interim data from a patient-reported survey describing early, real-world experience with Austedo XR. Eric Hughes, MD, PhD, executive VP of global …
Teva Presents Real-World Data for AUSTEDO ... - Teva …
Jun 2, 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …
Austedo | European Medicines Agency (EMA)
Jun 20, 2025 · The full indication will be as follows: Austedo is indicated for the treatment of moderate to severe tardive dyskinesia in adults. The initiation and titration of Austedo …
Teva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing …
Nov 2, 2024 · The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of tardive dyskinesia (TD), showing real-world treatment patterns and outcomes with …
Austedo for Tardive Dyskinesia - Philadelphia Integrative …
May 17, 2024 · What is Austedo? Austedo (deutetrabenazine) is a medication approved by the FDA for the treatment of tardive dyskinesia (TD), a condition characterized by involuntary …
Neurocrine Biosciences debuts new data for effectiveness of …
Mar 20, 2025 · Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of …
Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse …